Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
PALM-ILD
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy and Safety of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease
4 other identifiers
interventional
344
29 countries
182
Brief Summary
The primary objective of this study is to evaluate the effect of 24-weeks of once daily treatment with TPIP versus placebo on exercise capacity in adults with PH-ILD.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_3
Started Jan 2026
Typical duration for phase_3
182 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 10, 2025
CompletedFirst Posted
Study publicly available on registry
September 17, 2025
CompletedStudy Start
First participant enrolled
January 7, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 30, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 30, 2028
September 29, 2026
September 1, 2026
3 years
September 10, 2025
September 24, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change in 6 Minute Walk Distance (6MWD) Measured at Peak Exposure From Baseline to Week 24
Baseline, Week 24
Secondary Outcomes (8)
Time From Randomization to First Clinical Worsening Over the 24-Week Treatment Period
Up to Week 24
Time From Randomization to First Major Morbidity or Mortality Event Over the 24-Week Treatment Period
Up to Week 24
Change From Baseline in N-Terminal Pro Hormone Brain Natriuretic Peptide (NT-proBNP) Plasma Concentration Over 24 Weeks
Baseline up to Week 24
Number of Participants With Greater Than or Equal to (>=) 30% Decrease in NT-proBNP or Who Maintained/Achieved Less Than (<) 300 Nanogram per Liter (ng/L) of NT-proBNP Level at Week 24
At Week 24
Change in 6MWD Measured at Trough Exposure From Baseline to Week 22
Baseline, Week 22
- +3 more secondary outcomes
Study Arms (2)
Treprostinil Palmitil Inhalation Powder
EXPERIMENTALParticipants will receive TPIP, once daily (QD), at a starting dose of 80 micrograms (μg) to maximum tolerated dose up to 1280 μg for 24 weeks.
Placebo
PLACEBO COMPARATORParticipants will receive a placebo matching TPIP QD for 24 weeks.
Interventions
Oral inhalation using a capsule-based dry powder inhaler device.
Eligibility Criteria
You may qualify if:
- Diagnosis of PH World Health Organisation (WHO) Group 3 associated with ILD \[including but not limited to idiopathic interstitial pneumonia (IIP), chronic hypersensitivity pneumonitis (HSP), connective tissue disease-associated interstitial lung disease (CTD-ILD), combined pulmonary fibrosis and emphysema (CPFE).
- Confirmation of fibrotic interstitial lung disease by centrally overread computed tomography (CT) scan performed at Screening or within prior 12 months.
- PH confirmed by right heart catheterization (RHC) at Screening or within 12 months prior to Screening, with the following hemodynamic findings:
- Mean pulmonary arterial pressure (mPAP) \>20 millimetre of mercury (mmHg) and
- Pulmonary capillary wedge pressure (PCWP) of ≤15 mmHg and
- Pulmonary vascular resistance (PVR) ≥4 wood units (WU).
- Minute walking distance (6MWD) ≥100 and ≤500 meters at two 6 minute walking test (6MWT)s at Screening performed at least 4 hours apart, with the difference between the 2 distances ≤15%.
- Participants receiving chronic medication for underlying disease (e.g., antifibrotic, immunomodulators, immunosuppressants, etc.) and/or phosphodiesterase 5 (PDE5) inhibitors, should be on this treatment for ≥90 days and on a stable dose for ≥30 days prior to Screening.
- Capable of giving signed informed consent as described in Section 10.1.5 which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
You may not qualify if:
- Diagnosis of Pulmonary Hypertension WHO Groups 1, 2, 4, or 5 (including sarcoidosis), or subtypes of PH WHO Group 3 other than interstitial lung disease.
- Primary diagnosis of chronic obstructive pulmonary disease (COPD) and/or forced expiratory volume in 1 second (FEV1)/ forced vital capacity (FVC) \<0.7 (based on screening or historical spirometry within the prior 6 months).
- Clinically significant left heart disease:
- evidence of clinically significant left-sided valvular heart disease,
- left ventricular failure with left ventricular ejection fraction (LVEF) \<45%
- echocardiography findings at Screening suggestive for postcapillary (or combined pre and postcapillary) PH, heart failure with preserved ejection fraction (HFpEF), or heart failure with mildly reduced ejection fraction (HFmrEF), including left atrial volume index (LAVI) \>34 millilitres per metre square (mL/m\^2)
- unstable ischemic heart disease
- unstable arrhythmia, including uncontrolled atrial fibrillation (rate-controlled arrhythmia or paroxysmal atrial fibrillation is allowed)
- Evidence of chronic thromboembolic disease or recent (within 6 months of Screening) acute pulmonary embolism.
- Known hypersensitivity or contraindication to treprostinil or TPIP or TPIP formulation excipients (e.g., mannitol, leucine).
- Current use of cigarettes or e-cigarettes: An adult who has smoked at least 100 cigarettes in his or her lifetime and who currently smokes either every day or some days.
- Current use of inhaled marijuana, recreational or medical (current use defined as used at least one or more times during the past 30 days prior to Screening) or expected use during the study.
- Any other medical or psychological condition including relevant laboratory abnormalities at Screening that, in the opinion of the Investigator, suggest a new and/or insufficiently understood disease and/or may present an unreasonable risk to the study participant as a result of his/her participation in this clinical trial, may impede their ability complete the study or the study assessments or confound the outcomes of the trial.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (185)
USA027
Phoenix, Arizona, 85013, United States
USA007
Fresno, California, 93720, United States
USA010
Los Angeles, California, 900275969, United States
USA023
Los Angeles, California, 90095, United States
USA020
San Francisco, California, 94143, United States
USA001
Santa Barbara, California, 93105-4349, United States
USA017
Gainesville, Florida, 32610, United States
USA006
Naples, Florida, 34102-5412, United States
USA026
St. Petersburg, Florida, 33707-6129, United States
USA028
Tampa, Florida, 33606, United States
USA002
Kansas City, Kansas, 66160, United States
USA005
New York, New York, 10016, United States
USA011
Durham, North Carolina, 27710, United States
USA015
Cincinnati, Ohio, 45267, United States
USA003
Bend, Oregon, 97701, United States
USA013
Philadelphia, Pennsylvania, 19140, United States
USA025
Salt Lake City, Utah, 84018, United States
USA008
Richmond, Virginia, 23230, United States
ARG010
Ciudad Autónoma de Buenos Aires, Buenos Aires, 01093, Argentina
ARG005
Ciudad Autónoma de Buenos Aires, Buenos Aires, C1060ABN, Argentina
ARG002
CiudadAutonoma de Buenos Aires, Buenos Aires, C1280AEB, Argentina
ARG003
Río Cuarto, Córdoba Province, X5800AEV, Argentina
ARG011
Rosario, Santa Fe Province, S2002KDS, Argentina
ARG008
San Miguel de Tucumán, Tucumán Province, T4000AXL, Argentina
ARG004
Córdoba, X5000KEH, Argentina
ARG001
Córdoba, X5003DCE, Argentina
AUS001
Camperdown, New South Wales, 2050, Australia
AUS006
Kingswood, New South Wales, 2747, Australia
AUS005
New Lambton Heights, New South Wales, 2305, Australia
AUS003
Westmead, New South Wales, 2145, Australia
AUS004
Auchenflower, Queensland, 4066, Australia
AUS002
South Brisbane, Queensland, 4101, Australia
AUT002
Innsbruck, 6020, Austria
AUT001
Linz, 4021, Austria
AUT003
Vienna, 1090, Austria
BEL002
Leuven, Vlaams Brabant, 3000, Belgium
BEL001
Anderlecht, 1070, Belgium
BRA001
Belo Horizonte, Minas Gerais, 30441-070, Brazil
BRA012
Porto Alegre, Rio Grande do Sul, 90035-074, Brazil
BRA007
Porto Alegre, Rio Grande do Sul, 90560-030, Brazil
BRA003
Porto Alegre, Rio Grande do Sul, 90610-000, Brazil
BRA010
Blumenau, Santa Catarina, 89030-101, Brazil
BRA005
Ribeirão Preto, São Paulo, 14085-000, Brazil
BRA002
São Paulo, 04024-002, Brazil
BRA006
São Paulo, 05403-000, Brazil
COL003
Bogotá D.C., Bogota D.C., 110131, Colombia
COL004
Bogotá, Cundinamarca, 111211, Colombia
COL002
Floridablanca, Santander Department, 681004, Colombia
COL001
Cali, Valle del Cauca Department, 760042, Colombia
CZE001
Prague, 14000, Czechia
DNK001
Aarhus N, Central Jutland, 8200, Denmark
FRA009
Nice, Alpes-Maritimes, 6001, France
FRA002
Marseille, Bouches-du-Rhône, 13015, France
FRA004
Angers, Maine-et-Loire, 49100, France
FRA007
Lille, Nord, 59037, France
FRA008
Saint Priest En Jarez, Pays de la Loire Region, 42270, France
FRA003
Le Kremlin-Bicêtre, Val-de-Marne, 94270, France
FRA001
Poitiers, Vienne, 86000, France
FRA010
Brest, 29200, France
FRA011
Bron, 69500, France
FRA005
Pessac, 33604, France
FRA006
Strasbourg, 67091, France
GEO002
Tbilisi, 0144, Georgia
GEO004
Tbilisi, 0159, Georgia
GEO003
Tbilisi, 0180, Georgia
GEO001
Tbilisi, 0186, Georgia
DEU001
Heidelberg, Baden-Wurttemberg, 69126, Germany
DEU005
Immenhausen, Baden-Wurttemberg, 34376, Germany
DEU012
Stuttgart, Baden-Wurttemberg, 70376, Germany
DEU003
München, Bavaria, 80335, Germany
DEU006
München, Bavaria, 80639, Germany
DEU007
München, Bavaria, 81377, Germany
DEU008
Bonn, North Rhine-Westphalia, 53127, Germany
DEU002
Essen, North Rhine-Westphalia, 45239, Germany
DEU009
Homburg, Saarland, 66424, Germany
DEU004
Dresden, Saxony, 1307, Germany
DEU011
Lübeck, Schleswig-Holstein, 23562, Germany
DEU010
Gauting, 82131, Germany
GRC003
Pátrai, Achaia, 26504, Greece
GRC002
Athens, Anatoliki Attiki, 106 76, Greece
GRC005
Kallithea, Attica, 17674, Greece
GRC004
Heraklion, Crete, 71500, Greece
GRC001
Thessaloniki, 54636, Greece
ISR003
Petah Tikva, Central District, 4941492, Israel
ISR002
Jerusalem, Jerusalem, 9112001, Israel
ISR005
Haifa, 3109601, Israel
ISR001
Haifa, 3436212, Israel
ISR004
Tel Aviv, 6423906, Israel
ITA011
Bologna, Emilia-Romagna, 40138, Italy
ITA010
Catania, 95123, Italy
ITA008
Milan, 20123, Italy
ITA007
Modena, 41124, Italy
ITA005
Monza, 20900, Italy
ITA013
Naples, 80131, Italy
ITA001
Pavia, 27100, Italy
ITA003
Roma, 161, Italy
ITA004
Rozzano, 20089, Italy
ITA012
Sassari, 07100, Italy
JPN006
Nagakute, Aichi-ken, 480-1195, Japan
JPN012
Seto, Aichi-ken, 489-8642, Japan
JPN011
Hirosaki, Aomori, 036-8563, Japan
JPN002
Narashino-shi, Chiba, 275-0006, Japan
JPN004
Narita-shi, Chiba, 286-8520, Japan
JPN001
Sapporo, Hokkaido, 060-8648, Japan
JPN007
Yokohama, Kanagawa, 236-0051, Japan
JPN010
Kyotoshi, Kyoto, 606-8507, Japan
JPN009
Matsumoto, Nagano, 390-8621, Japan
JPN005
Nagano, Nagano, 380-0928, Japan
JPN015
Sakai, Osaka, 590-0197, Japan
JPN017
Suita, Osaka, 564-8565, Japan
JPN013
Bunkyo-Ku, Tokyo, 113-8431, Japan
JPN008
Kiyose, Tokyo, 204-0023, Japan
JPN003
Shibuya City, Tokyo, 151-8528, Japan
JPN014
Chiba, 260-8677, Japan
JPN016
Tsukuba, 305-8576, Japan
MYS004
Alor Star, Kedah, 5460, Malaysia
MYS001
Kota Bharu, Kelantan, 15586, Malaysia
MYS003
Kuantan, Pahang, 25200, Malaysia
MYS002
Kuching, Sarawak, 93586, Malaysia
MYS005
Kajang, Selangor, 43000, Malaysia
MEX002
Monterrey, Nuevo León, 64460, Mexico
MEX001
Monterrey, Nuevo León, 64718, Mexico
MEX003
Mexico City, 14080, Mexico
NZL001
Christchurch, Canterbury, 8011, New Zealand
NZL002
Dunedin, Otago, 9010, New Zealand
PHL002
Iloilo City, 5000, Philippines
PHL001
Makati City, 1229, Philippines
PHL003
Manila, 1015, Philippines
PHL004
Quezon City, 1100, Philippines
POL002
Bialystok, 15276, Poland
POL006
Krakow, 31-202, Poland
POL004
Lublin, 20-718, Poland
POL001
Warsaw, 02-005, Poland
PRT002
Almada, Setúbal District, 2805-267, Portugal
PRT001
Lisbon, 1769-001, Portugal
ROU004
Cluj-Napoca, Cluj, 400371, Romania
ROU002
Târgu Mureş, Mureș County, 540136, Romania
ROU001
Timișoara, Timiș County, 300310, Romania
ROU003
Bucharest, 11461, Romania
SRB001
Belgrade, 11000, Serbia
SRB004
Belgrade, 11000, Serbia
SRB002
Kamenitz, 21102, Serbia
SRB003
Kragujevac, 34000, Serbia
KOR002
Incheon, 21565, South Korea
KOR001
Seoul, 03080, South Korea
KOR004
Seoul, 3722, South Korea
KOR006
Seoul, 6351, South Korea
KOR003
Seoul, 6591, South Korea
KOR005
Wŏnju, 26426, South Korea
ESP002
Palma de Mallorca, Balearic Islands, 7120, Spain
ESP005
L'Hospitalet de Llobregat, Barcelona, 8907, Spain
ESP010
Majadahonda, Madrid, 28222, Spain
ESP012
Barcelona, 8035, Spain
ESP004
Barcelona, 8036, Spain
ESP006
Madrid, 28041, Spain
ESP003
Madrid, 28046, Spain
ESP009
Madrid, 28304, Spain
ESP011
Santiago de Compostela, 15706, Spain
ESP001
Seville, 41009, Spain
ESP007
Toledo, 45007, Spain
CHE001
Basel, 4031, Switzerland
CHE002
Zurich, 8091, Switzerland
TWN004
Douliu City Yunlin County, 640, Taiwan
TWN003
Hsinchu, 300, Taiwan
TWN001
Kaohsiung City, 80756, Taiwan
TWN005
Taichung, 40447, Taiwan
TWN002
Taipei, 10002, Taiwan
TWN006
Taipei, 104, Taiwan
TUR003
Adana, 1250, Turkey (Türkiye)
TUR004
Ankara, 6010, Turkey (Türkiye)
TUR008
Ankara, 6560, Turkey (Türkiye)
TUR001
Bursa, 16059, Turkey (Türkiye)
TUR012
Eskişehir, 26040, Turkey (Türkiye)
TUR005
Kayseri, 38039, Turkey (Türkiye)
TUR009
Kocaeli, 41380, Turkey (Türkiye)
TUR011
Trabzon, 61080, Turkey (Türkiye)
GBR009
London, Greater London, W12 0HS, United Kingdom
GBR004
Sheffield, Yorkshire, S10 2JF, United Kingdom
GBR001
Bath, BA1 3NG, United Kingdom
GBR008
Belfast, BT9 7AB, United Kingdom
GBR007
Glasgow, G81 4DY, United Kingdom
GBR002
London, NW3 2QG, United Kingdom
GBR003
London, SW3 6NP, United Kingdom
GBR010
Salford, M6 8HD, United Kingdom
GBR005
Southampton, SO16 6YD, United Kingdom
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Study Director
Insmed Incorporated
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 10, 2025
First Posted
September 17, 2025
Study Start
January 7, 2026
Primary Completion (Estimated)
December 30, 2028
Study Completion (Estimated)
December 30, 2028
Last Updated
September 29, 2026
Record last verified: 2026-09
Data Sharing
- IPD Sharing
- Will not share